Agomab draws $100M for fi­bro­sis pipeline, adding to drum­beat of nine-fig­ure Se­ries C rounds

Agomab Ther­a­peu­tics has reeled in $100 mil­lion that is set to bankroll the Bel­gian biotech through a Phase II study in a sub­set of Crohn’s dis­ease and Phase 1 tri­als of oth­er in­ves­ti­ga­tion­al treat­ments for fi­brot­ic con­di­tions.

The Se­ries C, which was dis­closed Tues­day, could give Agomab the op­tion to ex­plore an even­tu­al Nas­daq list­ing or the po­ten­tial to part­ner on one or mul­ti­ple drug can­di­dates, CEO Tim Knot­nerus told End­points News. Fi­deli­ty Man­age­ment & Re­search Com­pa­ny led the round, which al­so in­clud­ed EQT Life Sci­ences, Canaan, KKR’s Dawn Bio­phar­ma and ex­ist­ing in­vestors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER